LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
PALI
Palisade Bio, Inc.
There isn't enough reported data to score PALI yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
PALI Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Weak | |
| Unavailable |
PALI's profitability and cash flow are currently under pressure. There isn't enough data to rate its revenue and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
PALI PE Valuation
PALI has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
PALI Forward outlook
There aren't enough analyst estimates for PALI to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the stronger earnings trend. Trailing diluted EPS is up 51% for LLY versus PALI down 116%.
PALI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$13.83 | +$71.28 |
| Q2 2024 | -$18.86 | +$118.90 |
| Q1 2024 | -$23.49 | +$196.32 |
| Q4 2023 | -$27.00 | +$328.85 |
| Q3 2023 | -$85.11 | -116% |
| Q2 2023 | -$137.76 | -115% |
| Q1 2023 | -$219.81 | +$1,874.33 |
| Q4 2022 | -$355.85 | +$2,186.65 |
PALI lost $13.83 per share over the past year, a smaller loss than the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over PALI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over PALI on profitability, with a higher operating margin.
PALI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2020 | $2.5K | 0% |
PALI's revenue is growing: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -2340% | N/A |
| Q1 2023 | -1012% | N/A |
| Q4 2020 | -175764% | -90461 points |
| Q3 2020 | -93745% | N/A |
| Q2 2020 | -77894% | N/A |
| Q1 2020 | -33064% | N/A |
| Q4 2019 | -85303% | N/A |
PALI's operating margin was −2340% last quarter, up 75555 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over PALI on cash generation, producing positive trailing cash flow while its opponent burns cash.
PALI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$11.8M | -$8.2M |
| Q2 2026 | -$7.6M | -$5.8M |
| Q1 2026 | -$3.9M | -$1.6M |
| Q4 2025 | -$3.1M | -$763K |
| Q3 2025 | -$3.6M | -$420K |
| Q1 2025 | -$2.3M | +$847K |
| Q4 2024 | -$2.4M | +$365K |
| Q3 2024 | -$3.1M | -$471K |
PALI has burned cash in almost every quarter: −$26M over the past year, against −$10M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over PALI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
PALI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +646K shares |
| 1 year | +4320% | +207M shares |
| 3 years | +73597% | +212M shares |
| 5 years | +6879452% | +212M shares |
PALI has 212M diluted shares, up 4320% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
PALI Net Leverage
PALI's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
PALI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 4.9 | Oversold |
PALI's weekly RSI is 33 (neutral) and its Stochastic is 5 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
PALI PE vs Healthcare Sector
PALI has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over PALI on trend strength, trading above more of its moving averages.
PALI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.32 | 14% below |
| 20 week MA | $1.73 | 34% below |
| 50 week MA | $1.82 | 37% below |
| 100 week MA | $1.47 | 22% below |
| 200 week MA | $7.14 | 84% below |
PALI is in a downtrend: it's below all five of its weekly moving averages, and 84% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over PALI on returns for 2026, with the stronger performance.
PALI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4,103.9 | $4,025.6 | -1.9% |
| 2021 | $4,025.6 | $1,252.5 | -69% |
| 2022 | $1,252.5 | $28.7 | -98% |
| 2023 | $28.7 | $8.85 | -69% |
| 2024 | $8.85 | $1.67 | -81% |
| 2025 | $1.67 | $2.15 | +29% |
| 2026 YTD | $2.15 | $1.14 | -47% |
PALI has finished lower in five of the last six years. It's down 47% so far in 2026.